State-of-the-art practice in 3VD CAD combining predictive score, contemporary CTO expertise, angiography-derived physiology, intravascular Imaging and P2Y12 mono therapy: The Multivessel TALENT

Read full text Summarise with VIRAT
Authors: Patrick W.J.C. Serruys, Asahi Oshima, A Wlodarczak, S Z Wlodarczak, H. Moellmann, Raúl Moreno, Manel Sabaté, Miłosz Dziarmaga, J Legutko, Marc Silvestri, Julien Lemoine, Nozomu Kanehama
+3 more Albert Chinhenzva, T Y Tsai, Yoshinobu Onuma
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Clinical outcomes after PCI for three-vessel disease (3VD) have improved with best-practice strategies exemplified by the SYNTAX II trial. The Supraflex Cruz SES, featuring a long valley-to-valley Z-connector, provides enhanced flexibility and pushability and may compete with the current best-in-class stents in complex lesions. Purpose We aimed to demonstrate the noninferiority of the Supraflex Cruz SES versus SYNERGY EES with patient oriented composite endpoint (POCE) with 3VD undergoing State-of-the-art PCI. Methods The Multivessel TALENT trial is a prospective, multicentre (54 centres across Europe), open-label, randomized controlled study comparing the clinical outcomes of PCI with Supraflex Cruz stents versus SYNERGY stents in patients with de novo 3VD without left main involvement. State-of-the-art PCI was applied to all patients, encompassing Heart Team decision-making guided by the SYNTAX Score II, functional assessment using quantitative flow ratio (QFR) by an independent corelab, stent optimization with IVUS/OCT, and prasugrel monotherapy following one month of dual antiplatelet therapy (DAPT). The primary endpoint was the one-year POCE, defined as all-cause death, any stroke, any myocardial infarction, or any revascularisation assessed in a non-inferiority statistical scheme. Results Between September 22, 2020, and September 26, 2024, a total of 1,548 patients were randomly assigned to treatment (774 in each group). At 12 months, the primary endpoint occurred in 117 patients (15.3%) in the Supraflex Cruz group and in 111 patients (14.6%) in the SYNERGY group (absolute difference −0.73% [one-sided 95% upper confidence bound 3.73%]; p for non-inferiority

Fields of Study & Subjects

Coronary Interventions and Diagnostics Cardiac Imaging and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN